6 mg became the default nicotine pouch strength because regulators, not consumers, settled on the pouch as the unit of measurement — and 6 mg is the figure that clears every cap and fits a standard slim pouch. In the United States it is one of only two strengths the FDA has authorised for ZYN’s main line, and the only strength both authorised companies sell. In Europe it sits comfortably under every national ceiling. None of that was inevitable.
There is a tidy story about the 6 mg tier that goes roughly: it is the strength most people find comfortable, so the market converged on it. I do not think that story survives contact with the documents. What converged was regulation, and it converged on a particular way of counting — milligrams per pouch rather than milligrams per gram — which turned a manufacturing figure into a legal one. 6 mg is what you get when you take the concentration brands were already using and put it in a standard-sized pouch. The reason it is everywhere is that nothing stopped it being everywhere.
What a “6 mg” pouch actually means — and what it does not
Start with the unit, because it is where most confusion about strength begins. A pouch’s strength can be expressed two ways, and only one brand I could find publishes both. Nordic Spirit’s FAQ says the strength “can be shown in 2 ways, either as the milligrams (mgs) of nicotine per pouch” “or as the mgs of nicotine per gram,” and then does exactly that for its whole range (nordicspirit.co.uk, read 8 October 2026).
The result is the single most clarifying fact in this article. Nordic Spirit’s “Regular” standard pouch is “6mg of nicotine per pouch / 9mg of nicotine per gram.” Its Regular mini is “3mg of nicotine per pouch / 9mg of nicotine per gram.” Same concentration, half the nicotine — because the pouch is smaller. The 6 mg figure is therefore as much a statement about pouch mass as about dose. It is 9 mg/g in a standard slim pouch, and that is all it is.
That matters because pouch mass is not standardised. An independent measurement of seven brands found pouch weights from 0.25 g to 0.69 g — a 2.8-fold spread — with ZYN at 0.38 ± 0.002 g (Platt SP et al., Scientific Reports 2026;16:4406, doi 10.1038/s41598-025-34556-5). That study was funded by Altria Client Services, and I come back to what that means below. ZYN’s own site gives the same figure: “One ZYN pouch weighs approximately 0.4 grams” (us.zyn.com).
Here is the oddity. ZYN publishes a pouch weight and it publishes a strength, and it never joins them up: its US FAQ says “ZYN Nicotine Pouches are available in two nicotine strengths: 3 milligrams and 6 milligrams” without once saying whether that is per pouch or per gram (zyn.com/us/en, read 8 October 2026). VELO is explicit in the US — “approximately 3 milligrams,” “6 milligrams or 9 milligrams of nicotine per pouch” for VELO PLUS — and silent in Sweden, where products carry a bare “Styrka: 8MG” with no basis given, and publishes no milligram figures at all in the UK, where the range is labelled only “Mellow,” “Original” and “Intense” (velo.com/us; velo.com/se/sv; velo.com/en-gb). One company, three markets, three different levels of disclosure. If you want the long version of the units problem, we have a dedicated guide to mg per pouch versus mg per gram.
The United States fixed its legal market at a handful of numbers
This is the part of the story that is not market forces at all. The FDA’s list of authorised nicotine pouch products says, in the agency’s own words, “These are the only nicotine pouch products that may be lawfully sold in the United States.” The list carries 43 products from two companies and is content-current as of 21 August 2026 (FDA).
Read the names and the strengths are enumerated in every one. Helix Innovations has on! at 2 mg and 4 mg and on! PLUS at 6 mg and 9 mg. Swedish Match USA has ZYN at 3 mg and 6 mg across ten flavours, plus ZYN ULTRA at 9 mg across ten and ZYN ULTRA Smooth at 11 mg. The entire legal US market therefore runs on six numbers: 2, 3, 4, 6, 9 and 11 mg. There is no 5, no 7, no 8, no 10.
And 6 mg is the only one of the six that both authorised companies sell in their flagship lines — ZYN at 6 mg and on! PLUS at 6 mg. That is not a marketing convergence. It is the shape of two sets of marketing orders.
The regulator then went one step further in a way I think is decisive. On 30 June 2026 the FDA issued modified risk orders covering 20 ZYN products — the ten flavours “each with two nicotine strengths (3 milligram and 6 milligram)” — authorising the manufacturer to make this specific claim: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer,” “stroke, emphysema, and chronic bronchitis” (FDA, 30 June 2026).
Read the scope of that precisely, because it is narrow and conditional. It is a closed list of six named conditions, it is framed as a comparison against cigarettes, and the FDA’s own announcement attaches two limits: “An order permitting the sale of a modified risk tobacco product (MRTP) refers to specific products, not an entire class of tobacco products,” and “There is no safe tobacco product, and those who do not use tobacco products should not start.” The agency also says that “For adults who currently smoke cigarettes, fully quitting the use of all forms of tobacco products would most benefit their health.” That is the regulator’s claim, quoted; it is not this site’s claim, and it says nothing about anyone who does not already smoke.
But note which products it attaches to. The MRTP orders cover the 3 mg and 6 mg tier, not ZYN ULTRA. In the United States, the only nicotine pouches a company may legally advertise with an authorised reduced-risk claim are the low and mid tiers. If you are looking for a reason 6 mg became the centre of gravity, that is the strongest one on the record.
Europe capped the pouch, not the concentration
Europe arrived at a similar place by a different route, and the interesting thing is that the national caps do not agree on the number or the unit.
Denmark caps the pouch. Bekendtgørelse nr. 249 of 4 March 2025, in force 1 July 2025, says plainly: “Nikotinposer må maksimalt indeholde 9,0 mg nikotin pr. pose” — a maximum of 9.0 mg of nicotine per pouch, with no concentration limit at all (Retsinformation). Czechia caps the dose and the pack: decree 141/2023 Coll., effective 1 July 2023, sets “Jedna dávka nikotinového sáčku může obsahovat maximálně 12 mg nikotinu” and separately “Obsah jednotkového balení nesmí překročit 240 mg nikotinu.” Finland’s notified bill works per gram, at 16.6 mg per gram of product. Poland’s health ministry has published a 20 mg/g limit, and its own characterisation of the market before regulation is worth quoting: nicotine concentrations ranging “od 0–8 mg/g do nawet ponad 60 mg/g.”
Sweden, which has the oldest and largest market, has no cap at either level. I checked the primary act and the delegated regulation: lag (2022:1257) om tobaksfria nikotinprodukter contains no maximum nicotine figure, and Folkhälsomyndigheten’s föreskrifter HSLF-FS 2023:24 set none either — their only numeric provisions are label-coverage percentages (Riksdagen).
The United Kingdom has the power and has not used it. The Tobacco and Vapes Act 2026 s.96 lets the Secretary of State make regulations about “the substances that may be included in a relevant product or the amount of any given substance that may be included,” with “nicotine products” expressly in scope at s.96(2)(g) (legislation.gov.uk). As at 8 October 2026 legislation.gov.uk lists no secondary legislation made under it.
Underneath all of this sits the reason there is no EU-wide figure. The Tobacco Products Directive 2014/40/EU applies a material test: Article 2(4) defines “tobacco products” as “products that can be consumed and consist, even partly, of tobacco,” so a tobacco-free pouch is outside it, and the Directive sets no nicotine cap on one. The irony is that Article 2(8) describes the pouch format almost exactly — products “presented in sachet portions or porous sachets” — and still cannot reach a tobacco-free one, because the test is the material and not the form. Germany’s federal risk assessment body states the consequence bluntly: “Nicotine pouches are not subject to tobacco law” (BfR Opinion 027/2021, 20 September 2021). We track the national picture in detail in the global regulation tracker.
Put the four European numbers side by side and one thing falls out: a 6 mg standard pouch clears all of them with room to spare, and a 16.5 mg one does not come close. A strength that travels is a strength that gets manufactured.
The industry asked for the per-pouch unit, and got it
This is the part I found most surprising, and it is on the record in the manufacturer’s own annual report. In 2020 — before the FDA orders, before the Danish instrument — Swedish Match wrote that “Smokefree tobacco and nicotine regulation should ultimately be based upon standards” “(including appropriate maximum levels of nicotine per nicotine pouch)” “which strive to ensure that consumers receive attractive products” “with the highest possible product quality with minimal risk” (Swedish Match Annual Report 2020, p. 25).
The maker of ZYN chose the unit, in print, and argued for it. BfR independently proposed moving to a per-pouch basis in its own assessment. Denmark then legislated in exactly that unit. I would not call that a conspiracy — a per-pouch limit is arguably the more honest consumer-facing measure, since it is the pouch you put in your mouth — but it does mean the mainstream strength figure is downstream of a successful argument about what to count, and that argument was made by the company that sells the mainstream strength.
For contrast, BAT’s published product-standards framework asks regulators to “Establish nicotine content ceilings for non-tobacco products” and names no number and no unit (bat.com). Which is consistent with its disclosure behaviour: explicit milligrams per pouch in the US, an unexplained figure in Sweden, no figure at all in the UK.
What 6 mg actually delivers, and why the label is not the dose
None of the above tells you how much nicotine reaches you, and here the evidence genuinely splits — along funding lines.
The industry-funded study finds the label honest. Lunell E et al. measured content and extraction for ZYN at three strengths (Nicotine & Tobacco Research 2020;22(10):1757–1763, doi 10.1093/ntr/ntaa068). Measured content tracked the label almost exactly — 2.86 mg in the 3 mg pouch, 5.89 mg in the 6 mg, 7.52 mg in the 8 mg — and the extracted fraction was roughly flat at 55.9%, 59.1% and 50.4%. The funding statement is part of the result and the paper is unusually frank about it: “The present study was funded by Swedish Match AB, Stockholm, Sweden.” “The funder developed the protocol and an independent CRO conducted the studies.” “The funder has provided data, figures, and tables, but has in no way approved the manuscript.” Two of the four authors declare current consulting fees or employment from Swedish Match. (The publisher’s page serves only the abstract; I read the tables and the funding and interests statements from a mirrored copy of the paper PDF, and the abstract’s own figures are consistent with them.)
The regulator-funded study finds the opposite. Mallock-Ohnesorg N et al. tested 6, 20 and 30 mg pouches and concluded their results “also speak against a linear relationship between nicotine delivery and nicotine content in the pouch” (Frontiers in Pharmacology 2024;15:1392027, doi 10.3389/fphar.2024.1392027, published 22 May 2024). Extraction varied by product rather than by dose — 38% for the 6 mg pouch, 24% for the 20 mg, 52% for the 30 mg — and “Relative bioavailability in relation to the 6 mg (analyzed 4.8 mg) pouch was 70% for the 20 mg (analyzed 16.3 mg) pouch” and 165% for the 30 mg. That study was funded by “intermural funding from the German Federal Institute for Risk Assessment (BfR),” and its authors “declare that the research was conducted in the absence of any commercial or financial relationships” constituting a conflict.
So: the company-funded study says a 6 mg pouch delivers about twice a 3 mg one, and the state-funded study says you cannot read delivery off the label at all. I would not try to reconcile them. What I would take from both is that the number on the can is a specification, not a dose.
One figure from Lunell deserves its own sentence, because it corrects the instinct that 6 mg is a small amount. A ZYN 6 mg pouch delivered 3.5 mg of nicotine. An 8 mg General snus portion delivered 2.4 mg, and an 18 mg Longhorn Natural moist snuff dose delivered 3.0 mg. On that study, a 6 mg pouch out-delivers an 18 mg dip — because the pouch is alkaline and releases a much larger share of what it holds. If you want the mechanism, see pouch pH and why it changes the hit and snus vs dip vs chew.
Where 6 mg is not the default at all
The honest caveat. 6 mg is mainstream in the markets that regulate pouches tightly. It is not the Swedish norm. On VELO’s Swedish site there is exactly one 6 mg product in the range; the modal figure is 8 mg, across the SHIFT line, the Circuit Collection and Lime Flame, with Lundgrens products at 8, 10 and 12.5 mg. In a market with no cap, the middle of the range sat higher.
And there is a disclosure pattern worth naming. Every brand I could find that publishes a clear milligram ladder on its own site is a large-manufacturer subsidiary selling into a regulated market — ZYN, VELO, Nordic Spirit, Rogue (3 mg and 6 mg only, across all seven flavours, at roguenicotine.com). The independent extra-strong brands publish no first-party milligram figures I could reach at all: LOOP’s own site carries no milligram values anywhere, and for White Fox, Pablo and Klint I could not locate a manufacturer-controlled product page with strengths on it. The milligram figures circulating for those brands come from retailers. So the 6 mg tier is a disclosure regime as much as a dosing one — it is the strength of the part of the market that tells you its strengths.
The 6 mg tier in context
| Market or brand | Where 6 mg sits | Basis stated? | Ceiling |
|---|---|---|---|
| FDA authorised list (US) | One of six legal strengths; the only one both companies sell | Strength in product name; no basis given | 11 mg (ZYN ULTRA Smooth, one product) |
| ZYN US | Top of the main line (3 and 6 mg) | No | 11 mg via ZYN ULTRA |
| ZYN UK | “Medium” tier | No | 16.5 mg |
| VELO PLUS (US) | Middle of 3 / 6 / 9 mg | Yes — “per pouch” | 12 mg via VELO MAX |
| VELO Sweden | Lowest in the range; one product | No | 14 mg |
| VELO UK | Not published | No figures at all | Not published |
| Nordic Spirit | “Regular” standard pouch = 9 mg/g | Yes — both bases | 17 mg per pouch (24 mg/g) |
| Rogue | Top of the range | No | 6 mg |
| Denmark | Well under the cap | Statute: per pouch | 9.0 mg per pouch |
| Czechia | Well under the cap | Statute: per dose | 12 mg per dose; 240 mg per pack |
| Poland | Comfortably under | Ministry: per gram | 20 mg/g |
| Finland (notified bill) | Comfortably under | Per gram | 16.6 mg/g |
| Sweden | Below the market norm of 8 mg | — | No cap |
| United Kingdom | Mid-range | — | No cap; power exists, unexercised |
Frequently asked questions
Is 6 mg a beginner strength?
Two manufacturers point newcomers lower. ZYN’s UK site directs readers “New to nicotine pouches?” to “our 1.5mg & 3mg ranges,” and Nordic Spirit suggests its mini format for “existing adult nicotine users who are new to using nicotine pouches.” Both frame the audience as people who already use nicotine. No regulator I could find offers any guidance on which strength a new user should choose. We cover the decision in choosing your first nicotine pouch strength and the 3 mg tier.
Does a 6 mg pouch give me twice as much as a 3 mg one?
On the Swedish Match-funded pharmacokinetic study, roughly yes — 3.5 mg extracted versus 1.6 mg. On the BfR-funded study, labelled strength did not predict delivery at all. The two best studies disagree and the disagreement tracks who paid for them.
Is 6 mg per pouch or per gram?
It depends entirely on the brand, and most brands do not say. Nordic Spirit publishes both bases and is the exception. Where no basis is given and a pouch weighs about 0.4–0.6 g, a 6 mg-per-pouch figure corresponds to somewhere around 10–15 mg/g — but that is arithmetic from an assumed pouch weight, not a published number.
Why can I buy 16 mg pouches in the UK but not the US?
Because the two regimes work differently. The US requires premarket authorisation per product, and only 43 pouch products have it. The UK has the power to cap nicotine content in pouches under s.96 of the Tobacco and Vapes Act 2026 and has not yet used it.
Will 6 mg stay the mainstream strength?
I would not bet heavily either way. The FDA authorised ZYN ULTRA at 9 mg and 11 mg in August 2026, which widens the legal US ceiling for the first time. Against that, the modified risk orders still attach only to the 3 and 6 mg products, and the UK’s unexercised capping power is a standing possibility. See every brand’s strength scale compared for where the ladders currently sit, and the master ranking for what we rate.
Sources
- FDA, Nicotine Pouch Products Authorized by the FDA — 43 products, content current as of 21 August 2026. Read 8 October 2026.
- FDA, FDA Authorizes 20 ZYN Nicotine Pouches to Be Marketed with Specific Modified Risk Claim, 30 June 2026.
- Bekendtgørelse om grænseværdier for nikotinindhold i tobakssurrogater, nr. 249 af 4. marts 2025, Indenrigs- og Sundhedsministeriet; in force 1 July 2025.
- Vyhláška o nikotinových sáčcích bez obsahu tabáku, No. 141/2023 Coll. (Czechia), issued 16 May 2023, effective 1 July 2023, as notified to the Commission under Directive (EU) 2015/1535.
- Polish Ministry of Health, Prace nad ograniczeniem dostępu do wyrobów tytoniowych, 11 October 2024 — 20 mg/g limit and the pre-regulation market range.
- Lag (2022:1257) om tobaksfria nikotinprodukter (Sweden) — no nicotine cap; delegated power at 48 §.
- Tobacco and Vapes Act 2026 c.18, s.96 — power to regulate contents of nicotine products.
- Directive 2014/40/EU, Articles 2(4), 2(5) and 2(8).
- BfR, Preliminary health risk assessment of nicotine pouches, Opinion no. 027/2021, 20 September 2021.
- Lunell E, Fagerström K, Hughes J, Pendrill R. Pharmacokinetic comparison of a novel non-tobacco-based nicotine pouch (ZYN) with conventional, tobacco-based Swedish snus and American moist snuff. Nicotine & Tobacco Research 2020;22(10):1757–1763. doi 10.1093/ntr/ntaa068. Funded by Swedish Match AB.
- Mallock-Ohnesorg N et al. Small pouches, but high nicotine doses. Frontiers in Pharmacology 2024;15:1392027. doi 10.3389/fphar.2024.1392027. Funded by BfR; no competing interests declared.
- Platt SP et al. Dissolution and physical characterization of oral nicotine pouch products. Scientific Reports 2026;16:4406. Funded by Altria Client Services LLC; all authors Altria employees at the time of the study.
- Swedish Match, Annual Report 2020, p. 25.
- BAT, Our product standards framework. Read 8 October 2026.
- Manufacturer strength pages, all read 8 October 2026: ZYN US FAQ; us.zyn.com; ZYN UK strengths (published 27 July 2025); VELO US FAQ; VELO Sweden; VELO UK; Nordic Spirit FAQ; Rogue.
Last verified 8 October 2026.